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Background: The role of cytokines in various disease states is a burgeoning field of academic study and clinical
application, however there are no consensus documents on how certain cytokines should be stored prior to
quantification. This information is especially of interest to researchers assembling a biobank or clinicians who
have to transport specimens to a different location in order to be tested.
Objective: To review the literature and synthesize prior findings on cytokine storage and freeze/thaw stability.
Design: We searched PubMed for articles related to cytokine storage stability. All articles were analyzed for
cytokines studied, source of reported cytokine concentration (i.e., human whole blood or serum, concentrations
from other species or bodily sources were excluded), and reported statistical results.
Results: We identified and synthesized results of 23 peer-reviewed articles which published data on the storage
and freeze/thaw stability of 33 different cytokines and chemokines.
Conclusion: There is a wide variety of reported cytokine storage and freeze/thaw stability. Interleukin-6 and
tumor necrosis factor alpha are the most widely studied cytokines in regard to temperature stability. In a few
cytokines, a clear consensus can be reached as to storage safety at particular temperatures, but in most, more
research needs to be done and we advise the clinician or researcher to use caution in interpreting cytokine
concentration results after a long period of storage or several freeze/thaw cycles.
1. Introduction
Over the past 40 years our understanding of the role of cytokines in
the immune system has expanded rapidly [1], and along with that has
our ability to measure cytokines in blood. A growing body of research
has noted the clinical utility of accurate cytokine measurements to
predict everything from clinical outcomes in sepsis [2], likelihood of
schizophrenic patients to respond to medical treatment [3], develop-
ment of Alzheimer’s disease in the elderly [4], acceptance of transplant
organs [5], to bacterial infection in children [6]. With growing utility
for serum cytokine measurements both clinically and in research come
questions about the relationship between storage conditions and freeze-
thaw cycles and accuracy of results. This paper will review current
literature referencing this area of study and summarize findings. Its
purpose is to serve as a reference material for the clinician or researcher
who needs accurate assays of cytokine concentrations in patient blood.
Cytokines are proteins that have autocrine or paracrine signaling
mechanisms and are involved in promoting proliferation, differentia-
tion, and regulation of hematopoietic cells and other cells with host
defense functions; therefore determining the nature of an immune re-
sponse (Fig. 1) [7]. Chemokines are a group of structurally related
chemotactic agents for specific leukocytes that retain 4 cysteine re-
sidues which form disulfide bonds important for their tertiary structure
[8]. The most studied in regards to temperature stability are a subgroup
known as CC chemokines, named because the first two cysteines are in a
row (as opposed to CXC chemokines, where an amino acid is between).
Due to the rapid expansion in research on cytokines, it is critical to
know the concentration of various cytokines circulating in a patient to
gain information about a particular disease state. Currently, there are
many barriers to researchers creating normative cytokine levels;
amongst them the variety of cytokine quantification platforms, whether
the patient’s blood is collected in a tube with an anticoagulating agent,
the sterility of the sample, the storage conditions of the blood prior to
being analyzed, the number of freeze/thaw cycles the blood is exposed
to prior to analysis, and the process of degradation of the cytokine
being quantified [9] HYPERLINK "SPS:refid::bib9" .
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The purpose of this paper is not to establish reference ranges for
various cytokines in a multitude of health conditions, but rather to
examine the effects of storage and transport conditions on cytokine
levels, looking at each cytokine individually. Drawing on previous
published data and analyses, we offer summary statements on the sta-
bility of cytokine measurements in samples collected using different
blood collection tubes, stored at different temperatures for varying
lengths of time, and assayed using different cytokine quantification
platforms. This is necessary to assist both future researchers in the area
of immunological contributions to disease, and also in physicians
practicing direct patient care.
Each platform for cytokine quantification produces results that are
consistent within the platform itself, but not necessarily with other
assays (Table 1). Since each study utilized one type of assay for each
cytokine measured, and we are comparing only changes in cytokines
reported as significant within a study, we will only briefly touch on the
Fig. 1. Diagram showing interrelatedness of cytokines and their role in the immune system discussed in this paper. Boxes with a white background are cytokines.
Boxes with a blue background are immune cell types. Boxes with a green background are non-immune cell types. Orange call-outs are clinical responses. Blue lines
with arrows represent a positive correlation, orange lines with circle represent a negative correlation. (For interpretation of the references to colour in this figure
legend, the reader is referred to the web version of this article.)
Table 1
Cytokine Assay Platforms referenced in studies and commercial manufacturers.
Type of platform Commercial name Commercial manufacturer Location
Enzyme linked immunosorbent assay (ELISA) N/A R&D Systems Oxon, UK
Eurogenetics Tessenderlo, Belgium
Endogen Cambridge, Mass
Immunotech Marseilles, France
Genzyme Cambridge, Mass
Immunoradiometric Assay N/A Medgenix Brussels, Belgium
Bead-based multiplex immunoassay BIO-Plex 200 Bio-Rad Laboratories Hercules, CA
Luminex EMD Millipore Billerica, MA
Chip-based multiplex immunoassay EVIDENCE 180 Analyzer Randox Laboratories Crumlin, UK
Quantibody 18-Plex Raybiotech Norcross, GA
Electrochemiluminescence Meso Scale Discovery Assays MSD Rockville, MD
Immulite Automated Analyzer DPC Biermann Bad Nauheim, Germany
23 studies included in analysis 
191 studies on Pubmed matching 
search criteria 12/10/18 
168 studies excluded 
-23 not human 
-24 not serum 
-63 not testing cytokines 
-54 no temperature 
change speciﬁed 
-4 not in English 
Fig. 2. Flow Diagram of PubMed Search and included studies for analysis.
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3
differences between assays. Enzyme-linked immunosorbent assays
(ELISA) are historically used for cytokine analysis, and are known to
have a high sensitivity and specificity. Multiplex assays allow detection
of multiple analytes simultaneously, which can broaden researchers’
understanding of cytokine signaling cascades. There are bead-based
multiplex immunoassays that rely on fluorescence reporting such as a
cytometric bead assay (CBA) or Flometrix produced by Luminex [10],
and plate-based immunoassays such as the Meso Scale Discovery elec-
trochemiluminescence [11]. One of the reasons for a lack of inter-assay
agreement is the presence of endogenous plasma proteins including
heterophilic antibodies, soluble receptors, and complement which can
interfere with test findings [12,13].
Method of blood collection itself can impact results. Blood samples
collected in ethylenediaminetetraacetic acid (EDTA), heparin, or so-
dium citrate-containing tubes compared to those without additive may
yield varying levels of cytokines. When cytokines are measured in the
same patient, in blood samples collected at the same time and handled
in the same way, serum levels of cytokines are usually lower in those
containing anticoagulant samples [14,15]– this is believed to be due to
the presence of immunothrombosis, a theory that the introduction of
thrombus incites an immunologic response [16,17].
Source of cytokines – recombinant or endogenous – has been shown
to effect results. Three papers used blood samples spiked with cytokines
[18–20], with one of these papers comparing storage stability of spiked
cytokines versus endogenous cytokines [20]. This paper did find that
levels of spiked recombinant samples reacted differently than en-
dogenous cytokines, and that endogenous cytokines are actually more
stable. One reviewed study from healthy volunteers has also looked into
cytokine measurement reliability when samples were collected in
“sterile and non-pyrogenic” conditions (ie, endotoxin free containers)
versus following “normal” blood collection procedures, to be assured
that using a non-endotoxin free container did not incite cytokine release
[19]. Of the 6 cytokines evaluated, the only difference that was iden-
tified was IFNɣ concentration was significantly reduced when collected
under sterile non-pyrogenic procedures but was not reduced when
collected normally and stored under identical conditions. Differences in
sterile versus normal blood collection conditions and relevance to cy-
tokine measurements will not be further addressed in this paper.
Little is known about the optimal sample storage conditions for
future measurements of cytokines, which like other blood proteins can
degrade, or be released from cells after sample collection. When stored
as whole blood, this release can happen in less than 2 h [21]. Cytokines
themselves form a complex cascading communication network, and it is
presumed that the presence of cytokines in the blood sample when
taken from the patient could lead to the production and fluctuation in
levels of other cytokines in the cascade [1]. Addressing the stability of
various cytokines when stored at various temperatures or exposed to
repetitive freeze/thaw cycles is the focus of the remainder of this re-
view.
2. Methods
Our study is not intended as an exhaustive review of all cytokines.
Studies were identified to be included in this analysis by searching
PubMed for “cytokine AND stability AND human AND (temperature OR
storage) AND (blood OR plasma OR serum)”. This yielded 191 results
stretching back to 1971. Twenty-three studies were found to include
cytokines and the experimental treatment of undergoing freeze/thaw
cycles or extended storage at specific temperatures with measurements
of cytokine concentrations before and after the treatment and this
constituted the final sample for the focus of this paper wherein effect of
storage temperatures and number of sample freeze/thaw cycles on
measured concentrations of cytokines were assessed (Fig. 2).
Heterogeneity in the studied populations, targeted cytokines, ana-
lytic platform and statistical methodologies were noted and are sum-
marized in Table 2.Ta
bl
e2
(co
nti
nu
ed
)
Fir
st
au
th
or
an
dy
ea
r
Po
pu
lat
ion
an
ds
am
ple
siz
e
As
sa
y
Sta
tis
tic
al
too
lu
sed
in
an
aly
ses
Sta
tis
tic
al
sig
nifi
ca
nc
e
Co
mm
en
ts
Th
av
as
u[
19
]
63
he
alt
hy
vo
lun
tee
rs,
sp
ike
dw
ith
rec
om
bin
an
t
sta
nd
ard
s
Im
mu
no
-ra
dio
me
tri
c
as
sa
y
AN
OV
A
p
<
0.0
5
W
ho
le
blo
od
co
lle
cte
d,
pr
oc
ess
ed
,s
pik
ed
wi
th
rec
om
bin
an
tc
yto
kin
es,
ex
po
sed
to
ex
pe
rim
en
tal
co
nd
iti
on
,a
nd
tes
ted
va
nW
aa
ter
ing
e[
37
]
82
he
alt
hy
vo
lun
tee
rs,
75
pa
tie
nt
sw
ith
dia
be
tes
,8
3
pa
tie
nt
sw
ith
ah
ist
or
yo
fm
yo
ca
rd
ial
inf
arc
tio
n,
80
ob
ese
pa
tie
nt
se
nr
oll
ed
in
aw
eig
ht
-re
du
cti
on
pr
og
ram
EL
ISA
Pa
ssi
ng
-B
ab
lok
co
rre
lat
ion
,B
lan
d-A
ltm
an
an
aly
sis
un
cle
ar
W
ho
le
blo
od
co
lle
cte
d,
ke
pt
at
4C
for
90
mi
n,
pr
oc
ess
ed
,
fro
ze
n,
th
aw
ed
,a
liq
uo
ted
,r
e-f
ro
ze
n,
th
aw
ed
,e
xp
os
ed
to
ex
pe
rim
en
tal
co
nd
iti
on
,a
nd
tes
ted
Vi
nc
en
t[
14
]
10
pa
tie
nt
sw
ith
sy
ste
mi
cl
up
us
ery
th
em
ato
su
s
Ch
ip-
ba
sed
mu
lti
ple
x
im
mu
no
as
sa
y
Pa
ire
dt
-te
st
an
dW
ilc
ox
on
Sig
ne
dR
an
k
p
<
0.0
5
W
ho
le
blo
od
co
lle
cte
d,
pr
oc
ess
ed
,e
xp
os
ed
to
ex
pe
rim
en
tal
co
nd
iti
on
,f
ro
ze
n,
th
aw
ed
,a
nd
tes
ted
Za
nd
er
[3
8]
5p
oo
led
blo
od
ali
qu
ots
fro
m
cri
tic
all
yi
ll
pa
tie
nt
s
an
d5
po
ole
db
loo
da
liq
uo
ts
fro
m
ou
tpa
tie
nt
s
Be
ad
-ba
sed
mu
lti
ple
x
im
mu
no
as
sa
y
Co
effi
cie
nt
of
Va
ria
tio
na
nd
Re
fer
en
ce
Ch
an
ge
Va
lue
s
p
<
0.0
1
Se
ru
m
an
dc
itr
ate
sa
mp
les
we
re
po
ole
d,
pr
oc
ess
ed
,
ex
po
sed
to
ex
pe
rim
en
tal
co
nd
iti
on
,a
nd
tes
ted
S. Simpson, et al. Cytokine 125 (2020) 154829
4
When looking at the results of these studies below, it is important to
keep in mind that the studies are highly variable in the number of
patients analyzed, the type of patients recruited, sample handling, and
the robustness of statistical analysis. Also important to note is the stu-
dies that use recombinant cytokines spiked into human blood as the
recombinant cytokines may react differently from those produced
naturally by the immune system [18–20]. The results of the studies
using spiked recombinant cytokines are discussed at the end of the
paper.
3. The Interleukin-1 receptor cytokine family
Interleukin-1α, also known as IL-1F1, is a cytokine with proin-
flammatory properties that is part of the IL-1 system. IL-1α, IL-1β (or IL-
1F2), and IL-18 (IL-1F4) are agonists in the system, and interleukin-1
receptor antagonist or IL-1RA (or IL-1F3) is an antagonist in the system
[39]. Endotoxins from Gram-negative bacteria, exotoxins from Gram-
positive bacteria, T cells, tumor necrosis factor (TNF), IL-2, and lipo-
polysaccharides complexed with interferon gamma (IFNɣ) or
granulocyte-macrophage colony-stimulating factor (GM-CSF) can in-
duce IL-1 transcription. IL-4, IL-10, IL-13 and glucocorticoids suppress
IL-1 production. IL-1RA is produced by monocytes, macrophages,
polymorphonuclear neutrophils, and fibroblasts [39].
3.1. Interleukin-1α
IL-1α, when refrigerated as serum, or following plasma separation
using EDTA or heparin, appears stable for 6–30 days [15,19,30]
(Table 3.1a). Samples should not be left at room temperature for even
an hour prior to IL-1α quantification [19]. Additionally, all studies
except De Jager et al. [13] find IL-1α stable after 3–10 freeze/thaw
cycles in a variety of media [19,30,31] (Table 3.1b).
3.2. Interleukin-1β
Like IL-1α, IL-1β appears stable at 4C following plasma isolation
using citrate for 4 h, using EDTA for 48 h, or using heparin or as serum
for 6 days [14,19,30,36] (Table 3.2a). Samples should not be left at
Table 3.1a
IL-1α storage stability.
Sample type Anticoagulant Storage temp [C] Time in storage Statistically significant? Source
Plasma EDTA RT 1 h sig Thavasu et al. [19]
4C 10 h NS
4C 30 days NS Vincent et al. [15]
Plasma Heparin −80C 36months sig De Jager et al. [13]
4C 6 days NS Guo et al. [30]
RT 1 h sig Thavasu et al. [19]
4C 10 h NS
Serum None 4C 6 days NS Guo et al. [30]
RT 1 h sig Thavasu et al. [19]
4C 10 h NS
4C 30 days NS Vincent et al. [15]
Table 3.1b
IL-1α freeze/thaw stability.
Sample type Anticoagulant # of Freeze/Thaw Cycles Statistically significant? Source
Plasma Citrate 3 NS Hosnijieh et al. [31]
Plasma EDTA 6 NS Thavasu et al. [19]
Plasma Heparin 1 sig De Jager et al. [13]
10 NS Guo et al. [30]
6 NS Thavasu et al. [19]
Serum None 10 NS Guo et al. [30]
6 NS Thavasu et al. [19]
Table 3.2a
IL-1β storage stability.
Sample type Anticoagulant Storage temp [C] Time in storage Statistically significant? Source
Plasma Citrate RT 4 h sig Hennø et al. [14]
4C 4 h NS
Plasma EDTA RT 6 h NS Aguilar-Mahecha et al. [22]
RT 4 h sig Hennø et al. [14]
4C 4 h NS
35C 4 h sig Skogstrand et al. [36]
RT 4 h sig
4C 48 h NS
RT 10 h NS Thavasu et al. [19]
4C 10 h NS
Plasma Heparin −80C 36months sig De Jager et al. [13]
4C 6 days NS Guo et al. [30]
RT 10 h NS Thavasu et al. [19]
4C 10 h NS
Serum None 4C 6 days NS Guo et al. [30]
RT 10 h NS Thavasu et al. [19]
4C 10 h NS
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room temperature prior to quantification of IL-1β – most studies found
significant changes after just 4 h [14,19,22,36]. The evidence on
freeze/thaw stability is a little more diverse. It would appear frozen
storage of samples following plasma isolation in EDTA are least sus-
ceptible to significant changes [14,18,19,31,35] (Table 3.2b).
3.3. Interleukin-1RA
The results when looking at storage stability of IL-1RA at different
temperatures overall shows IL-1RA to be fairly unstable, with sig-
nificant differences shown in every combination of anticoagulant and
storage temperature except plasma isolated with citrate refrigerated
and serum at room temperature [14,15,24] (Table 3.3a). IL-1RA ap-
pears stable when quantified after freeze-thaw cycles in all media, al-
though Huang et al. [32] found a significant difference after 2 freeze-
thaw cycles for samples stored as sera [14,29,32] (Table 3.3b). More
research needs to be done as no anticoagulant has contesting or con-
firmatory data.
3.4. Interleukin-18
Interleukin-18 or IL-1F4 is a proinflammatory cytokine that is an
Table 3.3a
IL-1RA storage stability.
Sample type Anticoagulant Storage
temp [C]
Time in
storage
Statistically
significant?
Source
Plasma Citrate RT 4 h sig Hennø
et al. [14]4C 4 h NS
Plasma EDTA RT 24 h sig Aziz et al.
[24]4C 24 h sig
RT 4 h sig Hennø
et al. [14]4C 4 h NS
Plasma Heparin RT 24 h sig Aziz et al.
[24]4C 24 h sig
Serum None RT 24 h NS Aziz et al.
[24]4C 24 h sig
4C 30 days NS Vincent
et al. [15]
Table 3.2b
IL-1β freeze/thaw stability.
Sample type Anticoagulant # of freeze/thaw cycles Statistically significant? Source
Plasma Citrate 6 NS Hennø et al. [14]
1 sig Hosnijieh et al. [31]
Plasma EDTA 3 NS Hennø et al. [14]
6 sig
1 NS Parkitny et al. [35]
6 NS Thavasu et al. [19]
Plasma Heparin 1 sig De Jager et al. [13]
1 sig Guo et al. [30]
6 NS Thavasu et al. [19]
Serum None 1 sig Guo et al. [30]
1 sig Parkitny et al. [35]
2 NS Ray et al. [18]
6 NS Thavasu et al. [19]
Table 3.3b
IL-1RA freeze/thaw stability.
Sample type Anticoagulant # of Freeze/Thaw Cycles Statistically significant? Source
Plasma Citrate 6 NS Hennø et al. [14]
Plasma EDTA 6 NS Hennø et al. [14]
Plasma Heparin 5 NS Graham et al. [29]
Serum None 5 NS Graham et al. [29]
2 sig Huang et al. [32]
Table 3.4a
IL-18 storage stability.
Sample type Anticoagulant Storage temp [C] Time in storage Statistically significant? Source
Plasma EDTA 35C 4 h sig Skogstrand et al. [36]
RT 4 h sig
4C 48 h NS
4C 30 days NS Vincent et al. [15]
Plasma Heparin −80C 36months NS De Jager et al. [13]
Serum None 4C 30 days NS Vincent et al. [15]
Table 3.4b
IL-18 freeze/thaw stability.
Sample type Anticoagulant # of Freeze/thaw cycles Statistically significant? Source
Plasma Heparin 1 sig De Jager et al. [13]
5 NS Graham et al. [29]
Serum None 5 NS Graham et al. [29]
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agonist in the IL-1 system. It is part of a pathway leading to cell damage
by release of nitric oxide, reactive oxygen species, and TNFα [40]. It
plays an important role in defending against intracellular and extra-
cellular microbes and is thought to help defend against viral infections
as well.
Plasma separated with EDTA or heparin or stored as serum, at 4C is
stable for up to 30 days when quantifying IL-18 concentrations
[13,15,36] (Table 3.4a). De Jager, et al. [13] reports a difference in
concentration after only one freeze-thaw cycle in heparin, whereas
Graham et al. [29] finds IL-18 readings similar in up to 5 freeze-thaw
cycles in heparin and sera (Table 3.4b). De Jager et al. [13] has a
smaller sample size of 4 patients and uses samples stimulated with LPS,
while Graham et al. [29] has 140 patients and did not stimulate their
samples.
4. The Class I/hematopoietin receptor family of cytokines
The Class I or hematopoietin receptor family of cytokines all bind to
receptors that share similarities in their extracellular domains [41].
This receptor family can be broken down into subfamilies based on an
element of their heterodimeric or heterotrimeric receptors. IL-6 uses a
gp130 chain to bind; GM-CSF and IL-5 use a common β chain; IL-2, IL-4,
IL-7, IL-9, and IL-15 use a common ɣ chain, and IL-13 uses an α chain.
IL-12 and G-CSF do not belong to a subfamily but are classified by their
hematopoietin receptor.
4.1. Interleukin-6
The most well-studied cytokine to date is interleukin-6 (IL-6), per-
haps due to early recognition that this cytokine is upregulated in most
pathological states in humans. It has been implicated in sepsis, cancers,
inflammatory bowel conditions, and bone disease [7].
It appears that in all media tested, IL-6 remains stable at tempera-
tures at 4C and below for perhaps up to 30 days [14,15,24,34,36,37]
with the exception of the findings by de Jager et al. [13] that storage at
−80C for 36months results in a significant change from baseline
(Table 4.1a). De Jager’s controls were samples that were quantified
3 years earlier, possibly resulting in variability of their immunoassay
system.
Freeze/thaw cycles’ effects on IL-6 are more varied (Table 4.1b).
Parkitny et al. [35]) used an unusual statistical test, the intraclass
correlation coefficient (ICC) and their 95% confidence intervals based
on a two-way mixed-effects model and a Bland-Altman analysis. This is
a measure of reliability moreso than a measure of correlation, and goes
along with their explanation that they are testing the reliability of the
multiplex array system in addition to the experimental treatment of
freeze/thaw cycles [35]. Therefore, putting Parkitny’s results aside for
plasma isolated with EDTA or samples stored as serum, it would appear
freezing and thawing samples up to ten times before quantifying IL-6 is
not likely to affect IL-6 concentration [13,14,18,25,27,29,30,33]. In-
terestingly, in the citrate sample group, Hosnijieh et al. [31] and Hennø
et al. [14]; use the same experimental sample size of 10 healthy vo-
lunteers but analyze the data differently. Hennø compares his experi-
mental group with a totally different 182-person control group using
ANOVA and Hosnijieh compares his samples in a before and after
method with Spearman’s rank correlation coefficients. In general, in
plasma separated with EDTA or heparin, or samples stored as serum, it
is probably safe to expose a sample to up to 3 and possibly as many as
6–10 freeze/thaw cycles prior to inducing any significant changes in IL-
6 concentration.
4.2. Granulocyte-macrophage colony-stimulating factor
Granulocyte-macrophage colony-stimulating factor (GM-CSF) aug-
ments the activity of phagocytes like neutrophils, macrophages, den-
dritic cells, and eosinophils [42].
No one except Skogstrand et al. [36] has researched storage stability
of GM-CSF but this group’s findings would make it appear that plasma
stored in EDTA tubes could spend 4 h at room temperature prior to
quantifying GM-CSF and be accurate (Table 4.2).
4.3. Interleukin-5
Interleukin-5 (IL-5) is produced by T-cells and has an important role
in eosinophil response to allergens and parasites [43].
There is no agreement in findings for IL-5 stability in storage or after
freeze-thaw cycles. At this point, more research should be done, and
Table 4.1a
IL-6 storage stability.
Sample type Anticoagulant Storage
temp
[C]
Time in
storage
Statistically
significant?
Source
Plasma Citrate RT 4 h sig Hennø et al.
[14]4C 4 h NS
RT 24 h NS Peck Palmer
et al. [34]4C 24 h NS
−80C 24 h NS
Plasma EDTA RT 6 h sig Aguilar-
Mahecha
et al. [22]
RT 24 h NS Aziz et al.
[24]4C 24 h NS
RT 4 h sig Hennø et al.
[14]4C 4 h NS
RT 24 h NS Peck Palmer
et al. [34]4C 24 h NS
−80C 24 h NS
35C 48 h NS Skogstrand
et al. [36]RT 24 h sig
4C 48 h NS
RT 1 h sig Thavasu
et al. [19]4C 1 h sig
−80C 4 years NS van
Waateringe
et al. [37]
4C 30 days NS Vincent
et al. [15]
Plasma Heparin RT 24 h sig Aziz et al.
[24]4C 24 h NS
RT 8 h NS Friebe et al.
[28]4C 24 h NS
−20C 24 h NS
−80C 24 h NS
4C 6 days NS Guo et al.
[30]
−80C 36months sig De Jager
et al. [13]
RT 24 h NS Peck Palmer
et al. [34]4C 24 h NS
−80C 24 h NS
RT 1 h sig Thavasu
et al. [19]4C 1 h sig
Serum None RT 24 h NS Aziz et al.
[24]4C 24 h NS
RT 4 h sig Flower et al.
[27]4C 4 h NS
RT 8 h NS Friebe et al.
[28]4C 24 h NS
−20C 24 h NS
−80C 24 h NS
4C 6 days NS Guo et al.
[30]
40C 11 days sig Kenis et al.
[33]30C 21 days NS
20C 21 days NS
4C 21 days NS
−20C 21 days NS
4C 30 days NS Vincent
et al. [15]
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clinical or research applications relying on IL-5 concentrations should
quantify IL-5 expeditiously [13,14,22,31,35,36] (Tables 4.3a and 4.3b).
4.4. Interleukin-2
Interleukin-2 (IL-2) is mainly produced by CD4+ T cells that have
been activated by an antigen [44]. IL-2 amplifies the T-cell immune
response and can increase the proliferation of both cytotoxic and sup-
pressor T-cells.
The existing data shows IL-2 is stable when left at room temperature
in plasma isolated using EDTA for up to 6 h, or when refrigerated using
heparin or as serum for at least 6 days [13,22,30] (Table 4.4a). When
quantified after freeze/thaw cycles, only De Jager et al. [13] shows a
difference after 1 cycle (Table 4.4b). Brøndum et al. [25] and Guo et al.
[30] both show stability of IL-2 levels in heparin after at least 4 freeze/
thaw cycles, which represent 128 patient samples as opposed to de
Jager’s 4.
4.5. Interleukin-4
Interleukin 4 (IL-4) is important for the adaptive immune response
by increasing B cell surface major histocompatibility complex antigens
and stimulating growth of helper and cytotoxic T cells [45]. It is se-
creted by T cells, natural killer T cells, basophils, eosinophils, and mast
cells.
The majority of evidence shows that IL-4 is stable when refrigerated
in plasma separated by EDTA for at least 2 days, and separated by he-
parin or as serum for up to 6 days [14,30,36] (Table 4.5a). Citrate
storage produces less reliable data based on current studies [14]. As for
freeze/thaw cycles, the results show a fairly unstable cytokine with
significant changes after just 1 freeze/thaw cycle except in plasma
isolated by citrate [13,25,30,31,35] (Table 4.5b). Interestingly, De
Jager et al. [13] found that 1 freeze/thaw cycle of plasma separated by
heparin produced significant change, but when stored at −80C in he-
parin for three years, then quantified, the changes in IL-4 concentration
were not significant. In general, it seems quantifying IL-4 before
freezing samples would be advisable.
Table 4.1b
Freeze/thaw stability of IL-6.
Sample type Anticoagulant # of freeze/thaw cycles Statistically significant? Source
Plasma Citrate 6 NS Hennø et al. [14]
1 sig Hosnijieh et al. [31]
Plasma EDTA 6 NS Flower et al. [27]
6 NS Hennø et al. [14]
1 sig Parkitny et al. [35]
3 NS Thavasu et al. [19]
Plasma Heparin 4 NS Brøndum et al. [25]
5 NS De Jager et al. [13]
5 NS Graham et al. [29]
10 NS Guo et al. [30]
1 sig Thavasu et al. [19]
Serum None 5 NS Graham et al. [29]
10 NS Guo et al. [30]
4 NS Kenis et al. [33]
1 sig Parkitny et al. [35]
4 NS Ray et al. [18]
3 NS Thavasu et al. [19]
Table 4.2
GM-CSF Storage stability.
Sample type Anticoagulant Storage
temp [C]
Time in
storage
Statistically
significant?
Source
Plasma EDTA 35C 48 h NS Skogstrand
et al. [36]RT 4 h sig
4C 4 h sig
Table 4.3a
IL-5 storage stability.
Sample type Anticoagulant Storage temp [C] Time in storage Statistically significant? Source
Plasma Citrate RT 4 h sig Hennø et al. [14]
4C 4 h NS
Plasma EDTA RT 6 h NS Aguilar-Mahecha et al. [22]
RT 4 h sig Hennø et al. [14]
4C 4 h NS
35C 48 h NS Skogstrand et al. [36]
RT 4 h sig
4C 4 h sig
Plasma Heparin −80C 36months sig De Jager et al. [13]
Table 4.3b
IL-5 freeze/thaw stability.
Sample type Anticoagulant # of freeze/thaw Cycles Statistically significant? Source
Plasma Citrate 3 NS Hosnijieh et al. [31]
Plasma EDTA 1 sig Parkitny et al. [35]
Plasma Heparin 1 sig De Jager et al. [13]
Serum None 1 sig Parkitny et al. [35]
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4.6. Interleukin-7
Interleukin-7 (IL-7) is a non-redundant signaler for T-cell and B-cell
differentiation from hematopoietic stem cells [46].
The results show IL-7 quantification is stable when samples are
stored at 4C, though IL-7 may remain stable in plasma isolated by ci-
trate at room temperature for 4 h [14,22] (Table 4.6a). More research
needs to be done on stability after freeze/thaw cycles, currently
freezing IL-7 prior to quantification should not be done (Table 4.6b).
4.7. Interleukin-9
Interleukin-9 (IL-9) plays an important role in asthma and in para-
site response, signaling mast cell proliferation in the bone marrow [47].
IL-9 also specifically promotes mucin production in the lung epithe-
lium.
Hennø et al. [14] and Aguilar-Mahecha et al. [22] agree that IL-9 is
stable even at room temperature for up to 6 h in plasma when isolated
by EDTA (Table 4.7a). Hennø provides the only published reports on IL-
9 freeze-thaw cycles [14] (Table 4.7b). In all conditions studied, IL-9
appears stable.
4.8. Interleukin-15
Interleukin-15 (IL-15) helps protect against viral and bacterial in-
fections by stimulating NK cells, T cells, and B cells to proliferate and
secrete other cytokines; and by stimulating phagocytes [48] HYPERL-
INK "SPS:refid::bib48" .
More research needs to be done on storage stability and freeze-thaw
cycles (Tables 4.8a and 4.8b).
4.9. Interleukin-13
Interleukin-13 (IL-13) is produced by T cells, NK cells, basophils,
eosinophils, mast cells, dendritic cells, and lymphoma tumor cells [49].
It is important for allergic responses, healing and protection from hel-
minth infections, and asthmatic responses.
It would appear IL-13 is stable if refrigerated for at least 4 h as
Table 4.4a
IL-2 storage stability.
Sample type Anticoagulant Storage temp [C] Time in storage Statistically significant? Source
Plasma EDTA RT 6 h NS Aguilar-Mahecha et al. [22]
Plasma Heparin −80C 36months NS De Jager et al. [13]
4C 6 days NS Guo et al. [30]
Serum None 4C 6 days NS Guo et al. [30]
Table 4.4b
IL-2 freeze/thaw stability.
Sample type Anticoagulant # of Freeze/thaw cycles Statistically significant? Source
Plasma Citrate 3 NS Hosnijieh et al. [31]
Plasma Heparin 4 NS Brøndum et al. [25]
1 sig De Jager et al. [13]
10 NS Guo et al. [30]
Serum None 10 NS Guo et al. [30]
Table 4.5a
IL-4 storage stability.
Sample type Anticoagulant Storage temp [C] Time in storage Statistically significant? Source
Plasma Citrate RT 4 h sig Hennø et al. [14]
4C 4 h sig
Plasma EDTA RT 6 h sig Aguilar-Mahecha et al. [22]
RT 4 h sig Hennø et al. [14]
4C 4 h NS
35C 48 h NS Skogstrand et al. [36]
RT 48 h NS
4C 48 h NS
Plasma Heparin −80C 36months NS De Jager et al. [13]
4C 6 days NS Guo et al. [30]
Serum None 4C 6 days NS Guo et al. [30]
Table 4.5b
IL-4 freeze/thaw stability.
Sample type Anticoagulant # of freeze/thaw cycles Statistically significant? Source
Plasma Citrate 3 NS Hosnijieh et al. [31]
Plasma EDTA 1 sig Parkitny et al. [35]
Plasma Heparin 4 NS Brøndum et al. [25]
1 sig De Jager et al. [13]
1 sig Guo et al. [30]
Serum None 1 sig Guo et al. [30]
1 sig Parkitny et al. [35]
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plasma separated with citrate or EDTA [14,22] (Table 4.9a). Until
further study is completed, storage of IL-13 as plasma separated with
heparin is not recommended [13]. For freeze/thaw cycles, it would be
recommended that samples to be quantified for IL-13 be stored as serum
based on Parkitny et al.’s [35] (Table 4.9b) and Fraser et al.’s [20]
findings (Table 4.9a).
4.10. Interleukin-12
Interleukin-12 (IL-12) is a regulator of immune response, pre-
dominantly cell-mediated immunity [50]. It consists of two subunits:
p40 and p35. The p40 subunit is only expressed by antigen-presenting
cells such as monocytes, macrophages, and dendritic cells. The p35
subunit is expressed by many types of cells, but its production is tightly
regulated in antigen-presenting cells, thus controlling the amount of IL-
12 secreted.
Aguilar-Mahecha et al. [22], Aziz et al. [24], and Skogstrand et al.
[36] review the temperature storage stability of IL-12 (Table 4.10a).
When isolated by EDTA, plasma can be stored refrigerated for up to
48 h prior to quantifying IL-12 concentration [22,24,36]. When isolated
by heparin or stored as sera, further analysis is needed by other groups,
but Aziz et al.’s [24] findings suggest in heparin it is safe to store for up
to 24 h at room temperature or refrigerated prior to quantification [24].
As for freeze/thaw stability, only Hosnijieh et al. [31] showed com-
parable concentration of IL-12 after up to 3 freeze/thaw studies when
isolated in plasma by citrate [13,31,35] (Table 4.10b).
4.11. Granulocyte colony-stimulating factor
Granulocyte colony-stimulating factor (G-CSF) acts to produce
Table 4.6a
IL-7 storage stability.
Sample type Anticoagulant Storage temp [C] Time in storage Statistically significant? Source
Plasma Citrate RT 4 h NS Hennø et al. [14]
4C 4 h NS
Plasma EDTA RT 6 h NS Aguilar-Mahecha et al. [22]
RT 4 h sig Hennø et al. [14]
4C 4 h NS
Table 4.6b
IL-7 freeze/thaw stability.
Sample type Anticoagulant # of freeze/thaw Cycles Statistically significant? Source
Plasma EDTA 1 sig Parkitny et al. [35]
Serum None 1 sig Parkitny et al. [35]
Table 4.7a
IL-9 storage stability.
Sample type Anticoagulant Storage temp [C] Time in storage Statistically significant? Source
Plasma Citrate RT 4 h NS Hennø et al. [14]
4C 4 h NS
Plasma EDTA RT 6 h NS Aguilar-Mahecha et al. [22]
RT 4 h NS Hennø et al. [14]
4C 4 h NS
Table 4.7b
IL-9 freeze/thaw cycle stability.
Sample type Anticoagulant # of Freeze/thaw cycles Statistically significant? Source
Plasma Citrate 6 NS Hennø et al. [14]
Plasma EDTA 6 NS Hennø et al. [14]
Table 4.8a
IL-15 storage stability.
Sample type Anticoagulant Storage temp [C] Time in storage Statistically significant? Source
Plasma EDTA RT 6 h NS Aguilar-Mahecha et al. [22]
Plasma Heparin −80C 12months sig De Jager et al. [13]
Table 4.8b
IL-15 freeze/thaw cycle stability.
Sample type Anticoagulant # of freeze/thaw cycles Statistically significant? Source
Serum None 1 sig De Jager et al. [13]
S. Simpson, et al. Cytokine 125 (2020) 154829
10
neutrophils both at a basal level and in response to infection [51]. It is
produced by bone marrow stromal cells, fibroblasts, endothelial cells,
and activated macrophages.
The results here suggest G-CSF is better stored refrigerated or colder
for any length of time [14,22] (Table 4.11a). Parkitny et al. [35] found
significant differences after 1 freeze/thaw cycle when quantifying G-
CSF in plasma separated with EDTA or serum, while other researchers
found 3–4 freeze thaw cycles has no effect on concentration [25,32]
(Table 4.11b). Parkitny uses intraclass correlation coefficients, whereas
Brøndum et al. [25] uses t-tests and Huang et al. [32] uses Wilcoxon
Rank Sums to analyze data.
5. Class II cytokine receptor family
The Class II receptor family of cytokines includes interleukin-10 and
interferon cytokines. Like the Class I Receptor Family, this family binds
to receptors that share structural similarities in their extracellular do-
mains.
5.1. Interferon α
Interferon alpha (IFNα) is a type I interferon, which play important
roles in responding to viral infection, intracellular bacterial infections,
and endotoxin expressed by Gram-negative bacteria [52]. IFNα is
mainly secreted by lymphocytes.
Table 4.9a
IL-13 storage stability.
Sample type Anticoagulant Storage temp [C] Time in storage Statistically significant? Source
Plasma Citrate RT 4 h NS Hennø et al. [14]
4C 4 h NS
Plasma EDTA RT 6 h NS Aguilar-Mahecha et al. [22]
RT 4 h sig Hennø et al. [14]
4C 4 h NS
Plasma Heparin −80C 12months sig De Jager et al. [13]
Serum None −70C [QC] 4months NS Fraser
−70C [QC] 5months sig
−70C 15months NS
*QC = “quality control” recombinant cytokine spiked samples
Table 4.9b
IL-13 freeze/thaw stability.
Sample type Anticoagulant # of freeze/thaw cycles Statistically significant? Source
Plasma Citrate 1 sig Hosnijieh et al. [31]
Plasma EDTA 1 sig Parkitny et al. [35]
Plasma Heparin 4 NS Brøndum et al. [25]
1 sig De Jager et al. [13]
Serum None 1 NS Parkitny et al. [35]
Table 4.10a
IL-12 storage stability.
Sample type Anticoagulant Storage
temp [C]
Time in
storage
Statistically
significant?
Source
Plasma EDTA RT 6 h sig Aguilar-
Mahecha
et al. [22]
RT 24 h NS Aziz et al.
[24]4C 24 h NS
35C 48 h NS Skogstrand
et al. [36]RT 24 h NS
RT 48 h sig
4C 48 h NS
Plasma Heparin RT 24 h NS Aziz et al.
[24]4C 24 h NS
Serum None RT 24 h NS Aziz et al.
[24]4C 24 h sig
Table 4.10b
IL-12 freeze/thaw stability.
Sample type Anticoagulant # of freeze/thaw cycles Statistically significant? Source
Plasma Citrate 3 NS Hosnijieh et al. [31]
Plasma EDTA 1 sig Parkitny et al. [35]
Plasma Heparin 1 sig De Jager et al. [13]
Serum None 1 sig Parkitny et al. [35]
Table 4.11a
G-CSF storage stability.
Sample type Anticoagulant Storage temp [C] Time in storage Statistically significant? Source
Plasma Citrate RT 4 h sig Hennø et al. [14]
4C 4 h NS
Plasma EDTA RT 6 h sig Aguilar-Mahecha et al. [22]
RT 4 h sig Hennø et al. [14]
4C 4 h NS
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More studies need to be done to make recommendations regarding
stability of IFNα (Table 5.1). To date, no studies have examined the
effect of freeze/thaw on IFNα concentrations.
5.2. Interferon ɣ
Interferon gamma is produced by T lymphocytes and natural killer
cells in response to immune and inflammatory stimuli [53]. It is one of
the most well-studied cytokines and has roles in antiviral activity,
macrophage activation, innate immune responses, adaptive immune
responses (via increasing the number of major histocompatibility
complexes on cell surfaces for antigen presentation), T cell develop-
ment, humoral immunity, tumor immunity, and antiproliferation [53].
IFNɣ storage stability has been relatively well-studied (Table 5.2a).
IFNɣ appears stable when stored as plasma separated with EDTA or as
serum at 4C or colder for up to 30 days [15,19,22,24,30].
Besides Parkitny et al. [35] and De Jager et al. [13], when quanti-
fying IFNɣ, concentrations are accurate for at least 6 freeze-thaw cycles
if stored as plasma isolated by citrate and for at least 10 freeze thaw
cycles if isolated by EDTA or heparin, or stored as sera [14,23,30]
(Table 5.2b). Parkitny uses intraclass correlation coefficients for ana-
lysis which may explain the difference in significant findings.
5.3. Interleukin-10
Interleukin-10 (IL-10) has immunosuppressant capabilities, turning
off cytokine production by T cells, monocytes, macrophages, and den-
dritic cells [54]. IL-10 is expressed by activated T cells, B cells, mac-
rophages and monocytes, NK cells, keratinocytes, eosinophils, me-
sangial cells, epithelial cells, and tumor cells [54]. Its production is
induced by a variety of pathogens. In human disease, IL-10 has been
shown to improve inflammatory bowel disease [54].
For storage, Kenis et al. [33] and Guo et al. [30] agree that serum
samples should be kept at 4C if future quantification of IL-10 is desired
(Table 5.3a). IL-10 appears more stable when stored as plasma sepa-
rated with EDTA, with various reports showing stability even at room
temperature [22,36]. De Jager et al.’s [13] finding of a significant
difference after 3 years of storage at −80C in heparin may be related to
the elapsed time and potential introduction of bias [13].
With the exception of Guo et al. [30], all researchers have found
that freeze/thaw cycles do not affect the concentration of IL-10 when it
is stored as plasma isolated by citrate (up to 3 thaws), heparin (up to 5
thaws), and when stored as serum (up to 5 thaws) [13,18,33,30,31]
(Table 5.3b). Graham et al. [29] studied 140 patients compared to
Guo’s 9.
6. Tumor necrosis factor receptor family
The tumor necrosis factor (TNF) receptor family of cytokines are so
grouped together because the receptors all contain intracellular “death”
domains [41].
6.1. Tumor necrosis factor α
Tumor necrosis factor alpha (TNFα) has local effects that are im-
portant in host defense, but can be upregulated quickly and induce
systemic effects such as inflammation, hypotension, coagulation, and
tissue damage [55]. It is produced by monocytes in response to lipo-
polysaccharides, by epithelial cells in response to ultraviolet light, and
in T lymphocytes after receptor activation.
The published literature here is extensive. There is agreement
amongst papers using endogenous TNFα that when stored in plasma
isolated by EDTA, if stored at 4C or colder, TNFα is stable for at least
20 days [23,24,28,36,37] (Table 6.1a). If stored as serum at 4C, a ma-
jority of researchers found that TNFa remained stable for up to 30 days,
though possibly not 60 days [15,23,24,27,28,30,38]. When plasma was
separated using heparin, there is a little more variety in the results
[13,19,24,28,30]. Preferably, prior to quantification, TNFα would be
stored as serum or plasma isolated by EDTA.
Table 4.11b
G-CSF freeze/thaw stability.
Sample type Anticoagulant # of freeze/thaw cycles Statistically significant? Source
Plasma EDTA 1 sig Parkitny et al. [35]
Plasma Heparin 4 NS Brøndum et al. [25]
Serum None 3 NS Huang et al. [32]
1 sig Parkitny et al. [35]
Table 5.1
IFNα storage stability.
Sample type Anticoagulant Storage
temp [C]
Time in
storage
Statistically
significant?
Source
Plasma EDTA RT 1 h sig Thavasu
et al. [19]4C 10 h NS
Plasma Heparin RT 1 h sig Thavasu
et al. [19]4C 10 h NS
Serum None RT 1 h sig Thavasu
et al. [19]4C 10 h NS
Table 5.2a
IFNɣ storage stability.
Sample type Anticoagulant Storage
temp [C]
Time in
storage
Statistically
significant?
Source
Plasma EDTA RT 6 h sig Aguilar-
Mahecha
et al. [22]
RT 24 h NS Aziz et al.
[24]4C 24 h NS
RT 20 days NS Aziz et al.
[23]4C 20 days NS
−70C 20 days NS
35C 48 h NS Skogstrand
et al. [36]RT 4 h sig
4C 48 h NS
RT 1 h sig Thavasu
et al. [19]4C 1 h sig
Plasma Heparin RT 24 h NS Aziz et al.
[24]4C 24 h NS
4C 6 days NS Guo et al.
[30]
RT 1 h sig Thavasu
et al. [19]4C 1 h sig
Serum None RT 24 h NS Aziz et al.
[24]4C 24 h NS
RT 20 days NS Aziz et al.
[23]4C 20 days NS
−70C 20 days NS
4C 6 days NS Guo et al.
[30]
RT 1 h sig Thavasu
et al. [19]4C 1 h sig
4C 30 days NS Vincent
et al. [15]
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TNFα is a beta-pleated sheet type molecule and is more susceptible
to changes with freeze/thaw cycles [29]. This may explain, in part, the
variety of findings in Table 6.1b. For samples stored in plasma sepa-
rated with heparin, the only researcher to find a significant difference
was De Jager et al. [13], who used cytokines whose production was
stimulated by LPS, which may affect validity of results [19,25,29–30].
6.2. Tumor necrosis factor β
Tumor necrosis factor β, or lymphotoxin α, is expressed by T-lym-
phocytes and NK cells, and is important in lymphoid tissue develop-
ment and innate and adaptive immune response cellular differentiation
[56].
Skogstrand et al. [36] is uncontested, but it appears storage for 4 h
or less at room temperature or refrigerated does not affect TNFβ con-
centrations [36] (Table 6.2). Research needs to be done looking at re-
sponsiveness to freeze/thaw cycles. TNFβ, like TNFα, is a beta-pleated
sheet molecule and may be more susceptible to changes in freeze/thaw
cycles [29,56].
7. Chemokine receptor family
Chemokine receptors, as stated previously, are classified by their 7
transmembrane domains. All CXC and CC chemokines are included in
this family [41].
7.1. CC-motif chemokine ligand 2
CCL2 (CC-motif chemokine ligand 2) or MCP-1 (monocyte che-
moattractant protein 1) chemoattracts monocytes and induces them to
release enzymes [8].
Samples being quantified for CCL2 can be safely stored up to
30 days at 4C as plasma isolated by EDTA or in serum, but possibly not
even 4 h at room temperature prior to quantification [14,15,30,36]
Table 5.2b
IFNɣ freeze/thaw stability.
Sample type Anticoagulant # of freeze/thaw cycles Statistically significant? Source
Plasma Citrate 6 NS Hennø et al. [14]
3 NS Hosnijieh et al. [31]
Plasma EDTA 10 NS Aziz et al. [23]
6 NS Hennø et al. [14]
1 sig Parkitny et al. [35]
6 NS Thavasu et al. [19]
Plasma Heparin 1 sig De Jager et al. [13]
10 NS Guo et al. [30]
6 NS Thavasu et al. [19]
Serum None 10 NS Aziz et al. [23]
10 NS Guo et al. [30]
1 sig Parkitny et al. [35]
6 NS Thavasu et al. [19]
Table 5.3a
IL-10 storage stability.
Sample type Anticoagulant Storage temp [C] Time in storage Statistically significant? Source
Plasma EDTA RT 6 h NS Aguilar-Mahecha et al. [22]
35C 48 h NS Skogstrand et al. [36]
RT 48 h NS
4C 48 h NS
Plasma Heparin −80C 36months sig De Jager et al. [13]
4C 6 days NS Guo et al. [30]
Serum None 4C 6 days NS Guo et al. [30]
40C 21 days sig Kenis et al. [33]
30C 21 days sig
20C 21 days sig
4C 21 days NS
Table 5.3b
IL-10 freeze/thaw stability.
Sample type Anticoagulant # of freeze/thaw cycles Statistically significant? Source
Plasma Citrate 3 NS Hosnijieh et al. [31]
Plasma Heparin 5 NS De Jager et al. [13]
5 NS Graham et al. [29]
1 sig Guo et al. [30]
Serum None 4 NS Kenis et al. [33]
5 NS Graham et al. [29]
1 NS Parkitny et al. [35]
2 NS Ray et al. [18]
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(Table 7.1a). Graham et al. [29] and Guo et al. [30] both show that 5 or
more freeze/thaw cycles of plasma separated with heparin or stored as
serum do not significantly alter CCL2 concentrations (Table 7.1b). Once
again, Parkitny et al’s [35] findings disagree, possibly related to the
type of statistical test used that was trying to determine reliability of
their immunoassay system as well as the effect of the experimental
intervention [35].
7.2. CC-motif chemokine ligand 3
CC-motif chemokine ligand 3 (CCL3) or macrophage inflammatory
protein 1 alpha (MIP-1α) is produced by stimulated leukocytes, fibro-
blasts, and tumor cells, amongst others, and acts as a chemotactic agent
to monocytes, T cells, NK cells, dendritic cells, B cells, IgE-stimulated
mast cells, basophils, and eosinophils. CCL3 additionally causes
increased integrin expression in T cells, increased adhesions to en-
dothelial cell walls, and T-cell activation, proliferation, and secretion of
IL-2 [8].
It is unclear if storage of serum or plasma samples to later quantify
CCL3 is reliable at any temperature [22,36] (Table 7.2a). When stored
as plasma isolated by citrate, blood samples can be frozen and thawed
up to 6 times without significant change [14] (Table 7.2b).
7.3. CC-motif chemokine ligand 4
CC-motif chemokine ligand 4 (CCL4) or macrophage inflammatory
protein 1 beta (MIP-1β) is produced by stimulated leukocytes, fibro-
blasts, and tumor cells [8] CCL4 induces chemotaxis in T cells, mono-
cytes, NK cells, and dendritic cells.
Blood sample storage at room temperature to later check CCL4
concentration leads to statistically significantly different results
[22,24,36] (Table 7.3a). Refrigeration storage for samples stored as
serum and plasma separated with heparin have no differences after 24 h
[24]. EDTA-isolated plasma results vary [24,36]. One explanation is
Skogstrand et al. [36] used a p-value of 0.0625 as a cutoff and was more
likely to identify results as having significant differences when com-
pared with Aziz et al’s [24]cutoff of 0.05. CCL4 freeze/thaw cycles
show plasma samples separated with citrate that have been frozen and
thawed up to 6 times show no significant differences [14], and samples
in serum thawed twice with no significant difference [32] (Table 7.3b).
7.4. CC-motif chemokine ligand 5
CC-motif chemokine ligand 5 (CCL5) or RANTES is constitutively
expressed by unstimulated T cells, but is also expressed by platelets,
fibroblasts, and tumor cells [8]. Like CCL3 and CCL4, it induces che-
motaxis in monocytes, T cells, NK cells, and dendritic cells. CCL5 also
chemoattracts basophils, IgE-stimulated mast cells and eosinophils.
CCL5 quantification after storage at room temperature or 4C in
plasma separated with citrate or EDTA should be considered unreliable
[14,24,36] (Table 7.4a). CCL5 when stored as serum or as plasma iso-
lated by heparin may be able to sustain up to 24 h of refrigerated sto-
rage [24]. Measuring CCL5 after 3 freeze/thaw cycles in plasma sepa-
rated with citrate or EDTA appears to produce accurate readings,
however by the 6th thaw this is no longer the case [14,31] (Table 7.4b).
7.5. CC-motif chemokine ligand 11
CC-motif chemokine ligand 11 (CCL11), or eotaxin-1, is a che-
moattractant for eosinophils [8].
For short periods of time (4–6 h), in plasma separated with citrate or
EDTA, it is safe to keep CCL11 at room temperature or refrigerated
[14,22] (Table 7.5a). Blood samples being quantified for CCL11 can be
frozen and thawed at least 2 times in serum and up to 6 times in plasma
isolated by citrate and EDTA [14,25,31–32] (Table 7.5b).
7.6. C-X-C motif chemokine 10
C-X-C motif chemokine 10 (CXCL10), or interferon gamma-induced
protein 10 (IP-10), is produced by macrophages, T cells, fibroblasts,
endothelial cells, keratinocytes, synovial cells, and tumor cells. It is
constitutively expressed by thymic and splenic stromal cells [8].
CXCL10 appears to be fairly stable when stored for 4–6 h at room
temperature or refrigerated in plasma isolated by citrate and EDTA
[14,22], and when quantified after 3–6 freeze-thaw cycles [14,29,31]
(Tables 7.6a and 7.6b).
7.7. Interleukin-8
Interleukin-8 (IL-8), or CXCL8, has the traditional two pairs of cy-
steines with disulfide bond structure associated with chemokines [57].
Table 6.1a
TNFα storage stability.
Sample type Anticoagulant Storage
temp
[C]
Time in
storage
Statistically
significant?
Source
Plasma EDTA RT 6 h NS Aguilar-
Mahecha
et al. [22]
RT 24 h NS Aziz et al.
[24]4C 24 h NS
RT 20 days sig Aziz et al.
[23]4C 20 days NS
−70C 20 days NS
RT 8 h NS Friebe et al.
[28]4C 24 h NS
−20C 24 h NS
−80C 24 h NS
35C 48 h NS Skogstrand
et al. [36]RT 24 h sig
4C 48 h NS
RT 1 h sig Thavasu
et al. [19]4C 1 h sig
−80C 4 years NS van
Waateringe
et al. [37]
Plasma Heparin RT 24 h sig Aziz et al.
[24]4C 24 h NS
−80C 36months sig De Jager
et al. [13]
RT 8 h NS Friebe et al.
[28]4C 24 h NS
−20C 24 h NS
−80C 24 h NS
4C 6 days sig Guo et al.
[30]
RT 1 h sig Thavasu
et al. [19]4C 1 h sig
Serum None RT 24 h sig Aziz et al.
[24]4C 24 h NS
RT 20 days sig Aziz et al.
[23]4C 20 days NS
−70C 20 days NS
RT 4 h sig Flower et al.
[27]4C 4 h sig
RT 8 h NS Friebe et al.
[28]4C 24 h NS
−20C 24 h NS
−80C 24 h NS
4C 6 days NS Guo et al.
[30]
RT 1 h sig Thavasu
et al. [19]4C 1 h sig
4C 30 days NS Vincent
et al. [15]
4C 30 days NS Zander
20144C 60 days sig
−20C 90 days NS
−80C 90 days NS
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It is primarily produced by monocytes, but is also made by T cells,
neutrophils, natural killer cells, endothelial cells, fibroblasts, and epi-
thelial cells in response to proinflammatory cytokines like TNFα. It acts
as a chemotactic factor for neutrophils and induces degranulation of
neutrophils.
The majority of published reports show stability of IL-8 when re-
frigerated [14,22,28,36] (Table 7.7a). With plasma samples isolated by
heparin or in serum, Guo et al. [30] found significant differences when
Table 6.1b
TNFα freeze/thaw stability.
Sample type Anticoagulant # of freeze/thaw cycles Statistically significant? Source
Plasma Citrate 6 NS Hennø et al. [14]
1 sig Hosnijieh et al. [31]
Plasma EDTA 10 NS Aziz et al. [23]
3 sig Flower et al. [27]
6 NS Hennø et al. [14]
1 sig Parkitny et al. [35]
6 NS Thavasu et al. [19]
Plasma Heparin 4 NS Brøndum et al. [25]
1 sig De Jager et al. [13]
5 NS Graham et al. [29]
10 NS Guo et al. [30]
6 NS Thavasu et al. [19]
Serum None 10 NS Aziz et al. [23]
5 NS Graham et al. [29]
10 NS Guo et al. [30]
3 NS Ray et al. [18]
1 sig Parkitny et al. [35]
6 NS Thavasu et al. [19]
2 NS Huang et al. [32]
3 sig
Table 6.2
TNFβ storage stability.
Sample type Anticoagulant Storage
temp [C]
Time in
storage
Statistically
significant?
Source
Plasma EDTA 35C 48 h NS Skogstrand
et al. [36]RT 4 h sig
4C 4 h sig
Table 7.1a
CCL2 storage stability.
Sample type Anticoagulant Storage temp [C] Time in storage Statistically significant? Source
Plasma Citrate RT 4 h NS Hennø et al. [14]
4C 4 h NS
Plasma EDTA RT 4 h NS Hennø et al. [14]
4C 4 h NS
35C 48 h NS Skogstrand et al. [36]
RT 4 h sig
4C 48 h NS
4C 30 days NS Vincent et al. [15]
Plasma Heparin 4C 6 days NS Guo et al. [30]
Serum None 4C 6 days NS Guo et al. [30]
4C 30 days NS Vincent et al. [15]
Table 7.1b
CCL2 freeze/thaw stability.
Sample type Anticoagulant # of freeze/thaw cycles Statistically significant? Source
Plasma EDTA 1 sig Parkitny et al. [35]
Plasma Heparin 5 NS Graham et al. [29]
10 NS Guo et al. [30]
Serum None 5 NS Graham et al. [29]
10 NS Guo et al. [30]
1 sig Parkitny et al. [35]
Table 7.2a
CCL3 storage stability.
Sample type Anticoagulant Storage temp [C] Time in storage Statistically significant? Source
Plasma EDTA RT 6 h NS Aguilar-Mahecha et al. [22]
35C 24 h sig Skogstrand et al. [36]
RT 4 h sig
4C 48 h sig
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refrigerated for 6 days, but other studies show no significant changes
when refrigerated for 24 h [28,30]. De Jager et al. [13] shows a sig-
nificant difference in concentration after 12months at −80C, but as
addressed previously, bias could have been introduced into the analysis
system [13].
For freeze/thaw cycles, plasma separated with citrate has two stu-
dies supporting no significant change after at least 3 freeze/thaw cycles
with no conflicting data [14,31] (Table 7.7b). For plasma isolated by
heparin, there are 3 studies reporting no significant changes after 4 or
more freeze/thaw cycles, with the only conflicting evidence being De
Jager et al. [13,25,29–30]. Plasma isolated by EDTA and samples stored
as serum have less consistent results, though Huang et al. [32] supports
2 freeze/thaw cycles for samples in serum as having no significant
change [18,29–30,35]. If freezing samples for future quantification of
IL-8, we would recommend using citrate or heparin as anticoagulants.
8. Miscellaneous ligands and their receptors
The following are a combination of secreted ligands involved in
immune signaling and proper cytokines. They all have their own re-
ceptors that are not easily classified into the systems above.
8.1. Interleukin-16
Interleukin-16 (IL-16) is produced by CD8 and CD4+T cells, mast
cells, eosinophils, dendritic cells, bronchial alveolar cells, B cells, and
fibroblasts; and is a chemoattractant for CD4+ cells including eosino-
phils, monocytes, and dendritic cells [58]. Its receptor is actually the D4
region of CD4.
IL-16 is understudied in regard to temperature stability, more
research needs to be done (Table 8.1).
8.2. C-reactive protein
C-reactive protein (CRP) is induced by IL-6 and their serum levels
correlate in in vivo experiments [59]. It is important in acute phase
response systems to injury or infection. It binds to phosphocholine.
CRP, when stored as plasma isolated by citrate or heparin, is shown
to be stable by Peck Palmer et al. [34] for 24 h at a variety of tem-
peratures [34] (Table 8.2a). When stored as plasma separated with
EDTA, Skogstrand et al, 2008 [36] shows significant differences at just
4 h whereas Peck Palmer et al. [34] shows stability of CRP data when
stored for up to 24 h at room temperature or refrigerated, which is
contradictory. Both studies use bead-based multiplex immunoassays
and Wilcoxon Rank Sums to analyze data, but Peck Palmer has 16 pa-
tients compared to Skogstrand’s 5. For freeze/thaw cycles, Graham
et al. [29] shows no significant changes in quantification of CRP after 5
Table 7.2b
CCL3 freeze/thaw stability.
Sample type Anticoagulant # of freeze/thaw cycles Statistically significant? Source
Plasma Citrate 6 NS Hennø et al. [14]
Plasma EDTA 6 NS Hennø et al. [14]
1 sig Parkitny et al. [35]
Serum None 1 NS Parkitny et al. [35]
Table 7.3a
CCL4 storage stability.
Sample type Anticoagulant Storage
temp [C]
Time in
storage
Statistically
significant?
Source
Plasma EDTA RT 6 h sig Aguilar-
Mahecha
et al. [22]
RT 24 h NS Aziz et al.
[24]4C 24 h NS
35C 48 h NS Skogstrand
et al. [36]RT 4 h sig
4C 24 h sig
Plasma Heparin RT 24 h sig Aziz et al.
[24]4C 24 h NS
Serum None RT 24 h sig Aziz et al.
[24]4C 24 h NS
Table 7.3b
CCL4 freeze/thaw stability.
Sample type Anticoagulant # of freeze/thaw cycles Statistically significant? Source
Plasma Citrate 6 NS Hennø et al. [14]
Plasma EDTA 6 NS Hennø et al. [14]
1 sig Parkitny et al. [35]
Serum None 2 NS Huang et al. [32]
3 sig
Table 7.4a
CCL5 storage stability.
Sample type Anticoagulant Storage
temp [C]
Time in
storage
Statistically
significant?
Source
Plasma Citrate RT 4 h sig Hennø et al.
[14]4C 4 h sig
Plasma EDTA RT 24 h NS Aziz et al.
[24]4C 24 h NS
RT 4 h sig Hennø et al.
[14]4C 4 h NS
35C 4 h sig Skogstrand
et al. [36]RT 4 h sig
4C 4 h sig
Plasma Heparin RT 24 h sig Aziz et al.
[24]4C 24 h NS
Serum None RT 24 h NS Aziz et al.
[24]4C 24 h NS
Table 7.4b
CCL5 freeze/thaw stability.
Sample type Anticoagulant # of freeze/
thaw cycles
Statistically
significant?
Source
Plasma Citrate 3 NS Hennø et al.
[14]6 sig
3 NS Hosnijieh et al.
[31]
Serum EDTA 3 NS Hennø et al.
[14]6 sig
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cycles when stored as plasma isolated by heparin or as serum
(Table 8.2b). Huang et al. [32] shows significant changes in serum after
just 2 cycles. More research needs to be done on CRP freeze/thaw cy-
cles.
8.3. Epidermal growth factor
Epidermal growth factor (EGF) is a 53-amino-acid traditional
growth factor with cytokine-like actions. Its regulation and function are
not well understood, but it is believed to be involved in wound healing,
tissue regeneration, cytoprotection and angiogenesis, placentation, skin
homeostasis, and pathological states including cancer, polycystic
kidney disease, and psoriasis [60]. It binds to the epidermal growth
factor receptor, which is a receptor tyrosine kinase.
Only Guo et al. [30] has analyzed storage stability of EGF and more
research needs to be done to identify if EGF remains stable at any
temperature for a length of time [30] (Table 8.3a). Interestingly, Guo
reported that EGF concentrations in plasma isolated by heparin and
serum remained stable for up to 10 freeze-thaw cycles (Table 8.3b).
Huang et al. [32] confirms stability for up to 2 cycles but not 3 in serum
[32].
8.4. Interleukin-17
Interleukin-17 (IL-17) is a cytokine-inducing cytokine with in-
flammatory and hematopoietic activities, acting on a wide variety of
cell types. It has been implicated as playing a role in various auto-
immune diseases, including rheumatoid arthritis, systemic lupus
sclerosis, multiple sclerosis, and psoriasis [61]. It binds to its own re-
ceptor that does not have much homology with any of the other cyto-
kine receptor families.
The results here suggest that IL-17 is not a very stable cytokine
[13,35–36]. More research needs to be done to see if any length of
storage at any temperature is appropriate prior to evaluating IL-17
Table 7.5a
CCL11 storage stability.
Sample type Anticoagulant Storage temp [C] Time in storage Statistically significant? Source
Plasma Citrate RT 4 h NS Hennø et al. [14]
4C 4 h NS
Plasma EDTA RT 6 h NS Aguilar-Mahecha et al. [22]
RT 4 h NS Hennø et al. [14]
4C 4 h NS
Table 7.5b
CCL11 freeze/thaw stability.
Sample type Anticoagulant # of freeze/thaw cycles Statistically significant? Source
Plasma Citrate 6 NS Hennø et al. [14]
3 NS Hosnijieh et al. [31]
Plasma EDTA 6 NS Hennø et al. [14]
Plasma Heparin 4 NS Brøndum et al. [25]
Serum None 2 NS Huang et al. [32]
3 sig
Table 7.6a
CXCL10 storage stability.
Sample type Anticoagulant Storage temp [C] Time in storage Statistically significant? Source
Plasma Citrate RT 4 h NS Hennø et al. [14]
4C 4 h NS
Plasma EDTA RT 6 h NS Aguilar-Mahecha et al. [22]
RT 4 h NS Hennø et al. [14]
4C 4 h NS
Table 7.6b
CXCL10 freeze/thaw stability.
Sample type Anticoagulant # of freeze/thaw cycles Statistically significant? Source
Plasma Citrate 6 NS Hennø et al. [14]
3 NS Hosnijieh et al. [31]
Plasma EDTA 6 NS Hennø et al. [14]
Plasma Heparin 5 NS Graham et al. [29]
Serum None 5 NS Graham et al. [29]
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concentrations (Table 8.4a and 8.4b).
8.5. Transforming growth factor beta 1
Transforming growth factor beta 1 (TGFβ1) can be produced by
almost any cell but is mostly produced by platelets, and it is induced by
several markers of stress [62]. It has important, non-redundant roles in
hematopoiesis and immune cell homeostasis. Along with other mem-
bers of the TGFβ family, it binds to the TGFβ receptor family.
The limited studies that have been done on TGFβ stability indicates
that it should be stored at 4C or cooler for later quantification
(Table 8.5a), and that it may be frozen and thawed several times (or, up
to 100) [26,36] (Table 8.5b). Additional confirmatory studies would be
useful.
8.6. Vascular endothelial growth factor
Vascular endothelial growth factor (VEGF) is produced by
macrophages, platelets, and solid tumors. It induces endothelial vas-
cular growth and increases vascular permeability [63]. It is a major
focus of research on physiologic and pathologic angiogenesis. It binds
to one of three VEGF receptors.
Studies on VEGF temperature stability are dominated by Guo et al.
[30]). At this point, it appears safe to store serum and plasma separated
with heparin for up to 6 days at 4C [30] (Table 8.6a). There is con-
sensus that reliable quantification occurs in plasma isolated by heparin
to up to 4 and possibly 10 freeze/thaw cycles prior to quantification for
VEGF [25,30]; and in serum up to 2 freeze/thaw cycles prior to
quantification for VEGF [30,32] (Table 8.6b).
9. Samples spiked with recombinant cytokines
Ray et al. [18] studied freeze/thaw stability of recombinant TNFα,
IL-10, IL-1β, IL-6, and IL-8 in serum. Table 3.2b shows that Ray and
another recombinant cytokine study (Thavasu et al. [19] actually found
IL-1β concentration unchanged after 2–6 freeze/thaw cycles, as
Table 7.7a
IL-8 storage stability.
Sample type Anticoagulant Storage
temp
[C]
Time in
storage
Statistically
significant?
Source
Plasma Citrate RT 4 h NS Hennø et al.
[14]4C 4 h NS
Plasma EDTA RT 6 h NS Aguilar-
Mahecha
et al. [22]
RT 8 h NS Friebe et al.
[28]4C 24 h NS
−20C 24 h NS
−80C 24 h NS
RT 4 h sig Hennø et al.
[14]4C 4 h NS
35C 24 h sig Skogstrand
et al. [36]RT 24 h sig
4C 48 h NS
Plasma Heparin −80C 12months sig De Jager
et al. [13]
RT 8 h sig Friebe et al.
[28]4C 24 h NS
−20C 24 h NS
−80C 24 h NS
4C 6 days sig Guo et al.
[30]
Serum None RT 8 h sig Friebe et al.
[28]4C 24 h NS
−20C 24 h NS
−80C 24 h NS
4C 6 days sig Guo et al.
[30]
Table 7.7b
IL-8 freeze/thaw stability.
sample type Anticoagulant # of freeze/thaw cycles Statistically significant? Source
Plasma Citrate 6 NS Hennø et al. [14]
3 NS Hosnijieh et al. [31]
Plasma EDTA 6 NS Hennø et al. [14]
1 sig Parkitny et al. [35]
Plasma Heparin 4 NS Brøndum et al. [25]
1 sig De Jager et al. [13]
5 NS Graham et al. [29]
10 NS Guo et al. [30]
Serum None 5 NS Graham et al. [29]
10 NS Guo et al. [30]
2 NS Huang et al. [32]
3 sig
3 NS Ray et al. [18]
1 sig Parkitny et al. [35]
Table 8.1
IL-16 freeze/thaw stability.
Sample type Anticoagulant # of freeze/
thaw cycles
Statistically
significant?
Source
Serum None 2 NS Huang et al.
[32]3 sig
Table 8.2a
CRP storage stability.
Sample type Anticoagulant Storage
temp [C]
Time in
storage
Statistically
significant?
Source
Plasma Citrate RT 24 h NS Peck Palmer
et al. [34]4C 24 h NS
−80C 24 h NS
Plasma EDTA 35C 4 h sig Skogstrand
et al. [36]RT 4 h sig
4C 4 h sig
RT 24 h NS Peck Palmer
et al. [34]4C 24 h NS
−80C 24 h NS
−80C 4 years NS van
Waateringe
et al. [37]
Serum Heparin RT 24 h NS Peck Palmer
et al. [34]4C 24 h NS
−80C 24 h NS
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compared to endogenous cytokine studies where even 1 freeze/thaw
cycle induced change [30,35].
Thavasu et al. [19] used recombinant TNFα, IFNα, IFNɣ, IL-1α, IL-
1β, and IL-6. In most of these instances, their findings were consistent
with others’, however Table 4.1a and 4.1b emphasize that recombinant
IL-6 appeared less stable than endogenous IL-6 when stored in plasma
separated by EDTA or heparin. Table 5.2a also shows that recombinant
IFNɣ is less stable than endogenous IFNɣ when refrigerated as serum or
after separation with heparin or EDTA. Thavasu was the only researcher
who looked at IFNα (Table 5.1), so it is difficult to draw conclusions
about endogenous IFNα cytokine behavior.
Fraser et al’ [20] study looked at recombinant IL-13 storage stability
(Table 4.9a) and found when compared to endogenous IL-13 stored as
serum, it did not go as long without significant concentration changes.
10. Conclusions
Although much of the existing research is conflicting, certain cyto-
kines seem more stable when exposed to different storage temperatures
or a different number of freeze/thaw cycles prior to quantification, such
as IL-9, CXCL10, and eotaxin-1. Cytokines that are especially unstable
or for which no clear consensus exists should be assayed as soon as
possible after the blood sample is collected, such as IL-1RA, IL-4, and IL-
Table 8.2b
CRP freeze/thaw stability.
Sample type Anticoagulant # of freeze/thaw cycles Statistically significant? Source
Plasma Heparin 5 NS Graham et al. [29]
Serum None 5 NS Graham et al. [29]
2 sig Huang et al. [32]
Table 8.3a
EGF storage stability.
Sample type Anticoagulant Storage temp [C] Time in storage Statistically significant? Source
Plasma Heparin 4C 6 days sig Guo et al. [30]
Serum None 4C 6 days sig Guo et al. [30]
Table 8.3b
EGF freeze/thaw stability.
Sample type Anticoagulant # of freeze/thaw cycles Statistically significant? Source
Plasma Heparin 10 NS Guo et al. [30]
Serum None 10 NS Guo et al. [30]
2 NS Huang et al. [32]
3 sig
Table 8.4a
IL-17 storage stability.
Sample type Anticoagulant Storage temp [C] Time in storage Statistically significant? Source
Plasma EDTA 35C 4 h sig Skogstrand et al. [36]
RT 4 h sig
4C 4 h sig
Serum Heparin −80C 36months sig De Jager et al. [13]
Table 8.4b
IL-17 freeze/thaw stability.
Sample type Anticoagulant # of freeze/thaw cycles Statistically significant? Source
Plasma Heparin 1 sig De Jager et al. [13]
Serum None 1 sig Parkitny et al. [35]
Table 8.5a
TGFβ storage stability.
Sample type Anticoagulant Storage
temp [C]
Time in
storage
Statistically
significant?
Source
Plasma EDTA 35C 48 h NS Skogstrand
et al. [36]RT 48 h sig
4C 48 h NS
Serum None 37C 24 h sig Chaigneau
et al. [26]
Table 8.5b
TGFβ freeze/thaw stability.
Sample type Anticoagulant # of freeze/thaw cycles Statistically significant? Source
Serum None 100 NS Chaigneau et al. [26]
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5. The reasons some cytokines are more unstable than others may be
related to the speed of degradation, the cytokine being secreted after
blood has been collected, or the structure of the cytokine itself.
Some cytokines and chemokines have not been studied at all, and
further work needs to be done to assure that storage mechanisms and
freeze/thaw practices produce reliable results when quantifying cyto-
kines. As there becomes more of a role for accurate cytokine mea-
surement in research and for direct patient-care purposes, this body of
research will help guide lab storage practices.
This paper, to our knowledge, is the first of its kind presenting a
synthesized review of temperature stability of cytokines, organized by
cytokine, which can be used for easy reference for the clinician or re-
searcher to determine how blood samples need to be handled prior to
cytokine quantification to assure the most accurate results.
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